Loading patent…
AssigneeShire LLC
InventorsRoger Withington, David Pierce, Josephine Christine Ferdinando, Peter Neil Davies
Estimating the term…
The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.
An oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant.
-40. (canceled)
An oral pharmaceutical powder comprising (1) lanthanum carbonate or lanthanum carbonate hydrate, (2) dextrates, (3) colloidal silicon dioxide, and (4) magnesium stearate, wherein the elemental lanthanum as lanthanum carbonate or lanthanum carbonate hydrate is in an amount from about 26 wt % to about 50 wt % by weight of the powder.
A method of treating hyperphosphatemia in a patient comprising administering to the patient an oral pharmaceutical powder comprising (1) lanthanum carbonate or lanthanum carbonate hydrate, (2) dextrates, (3) colloidal silicon dioxide, and (4) magnesium stearate, wherein the elemental lanthanum as lanthanum carbonate or lanthanum carbonate hydrate is in an amount from about 26 wt % to about 50 wt % by weight of the powder.
A method of treating a patient (1) at risk of or suffering from chronic kidney disease (CKD), (2) at risk of or suffering from soft tissue calcification associated with chronic kidney disease (CKD), or (3) at risk of or suffering from secondary hyperparathyroidism comprising administering to the patient an oral pharmaceutical powder comprising (1) lanthanum carbonate or lanthanum carbonate hydrate, (2) dextrates, (3) colloidal silicon dioxide, and (4) magnesium stearate, wherein the elemental lanthanum as lanthanum carbonate or lanthanum carbonate hydrate is in an amount from about 26 wt % to about 50 wt % by weight of the powder.
Dependencies are inferred from the claim text.